News for Moleculin Biotech, Inc. (MBRX)

PR NewswireHOUSTON, March 11, 2025 On-demand video webcast now available hereHOUSTON, March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX

PR NewswireHOUSTON, March 10, 2025 Live webcast fireside chat on Tuesday, March 18th at 11:00 AM PTHOUSTON, March 10, 2025 /PRNewswire/ -- Moleculin Biotec

PR NewswireHOUSTON, Feb. 25, 2025 HOUSTON, Feb. 25, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-sta

Israel-based Femto Technologies Inc. (FMTO) is up over 114 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Ohio-based Energy Focus, Inc. (EFOI) is up over 63 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) made a strategic move by acquiring an additional 49,767 shares of Moleculin Biotech Inc (MBRX)

Texas-based Moleculin Biotech, Inc. (MBRX), a clinical stage pharmaceutical company is up over 53 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

U.S. stock futures traded close to the flatline on Friday after Tuesday's rally. Futures of all four benchmark indices were slightly lower.

Shares of Coherent Corp. COHR rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Coherent rep...

PR NewswireHOUSTON, Jan. 27, 2025 ”“ Walter Klemp, CEO of Moleculin, provides an update on the Company's Phase 3 pivotal trial of Annamycin for the treatm

Moleculin Biotech (MBRX) files for offering of common stock and warrants, size undisclosed.

PR NewswireHOUSTON, Dec. 11, 2024 Abstract published as part of the American Society of Hematology (ASH) Annual MeetingStudy shows Annamycin effectively ta

PR NewswireHOUSTON, Nov. 18, 2024 Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Veneto

Nov 11, 2024 / 01:30PM GMTOperator Greetings, and welcome to the Moleculin Biotech quarterly update conference call and webcast. (Operator Instructions) As a re

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Conference Call November 11, 2024 8:30 AM ETCompany ParticipantsJenene Thomas - IRWalter Klemp -...

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Release Date: August 06, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Moleculin Biot

Aug 06, 2024 / 12:30PM GMTOperator Greetings and welcome to the conference call where Moleculin Biotech discusses plans for MIRACLE Phase 3 pivotal trial. (Oper

Moleculin Biotech gets Buy rating from Roth with strong trial results